Medical therapy for clinical benign prostatic hyperplasia:α1 Antagonists,5α reductase inhibitors and their combination  

作　　者：Cheuk Fan Shum Weida Lau Chang Peng Colin Teo 

机构地区：[1]Department of Urology,Khoo Teck Puat Hospital,Singapore

出　　处：《Asian Journal of Urology》2017年第3期185-190,共6页亚洲泌尿外科杂志（英文）

摘　　要：Medical therapy for clinical benign prostatic hyperplasia(BPH)has advanced significantly in the last 2 decades.Many new a1 antagonists and 5a reductase inhibitors(5ARi)are now commercially available.The practicing urologist must decide on the most appropriate medication for his patients,taking into consideration various factors like efficacy,dosing regime,adverse effects,cost,patient’s socioeconomic background,expectations,drug availability and his own clinical experience.The use of combination therapy added further to the complexity in clinical judgment when prescribing.We highlight some of the key points in prescribing a1 antagonists,5ARi and their combination,based on our viewpoints and experience as urologists in an Asian clinical setting.

关 键 词：5αReductase inhibitors Adrenergicα1 receptor antagonists Drug therapy COMBINATION Prostatic hyperplasia 

分 类 号：R73[医药卫生—肿瘤]